KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Research & Development (2020 - 2025)

Aurinia Pharmaceuticals' Research & Development history spans 6 years, with the latest figure at $10.9 million for Q4 2025.

  • For Q4 2025, Research & Development rose 34.39% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $32.5 million, up 56.39%, while the annual FY2025 figure was $32.5 million, 56.39% up from the prior year.
  • Research & Development reached $10.9 million in Q4 2025 per AUPH's latest filing, up from $8.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $20.1 million in Q3 2021 to a low of $3.0 million in Q3 2024.
  • Average Research & Development over 5 years is $9.5 million, with a median of $10.0 million recorded in 2021.
  • Peak YoY movement for Research & Development: soared 228.95% in 2023, then plummeted 77.6% in 2024.
  • A 5-year view of Research & Development shows it stood at $11.1 million in 2021, then decreased by 11.16% to $9.9 million in 2022, then rose by 3.63% to $10.2 million in 2023, then fell by 20.74% to $8.1 million in 2024, then soared by 34.39% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Research & Development are $10.9 million (Q4 2025), $8.4 million (Q3 2025), and $7.4 million (Q2 2025).